ONO-1110 + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postherpetic Neuralgia
Conditions
Postherpetic Neuralgia
Trial Timeline
Feb 12, 2025 → Aug 31, 2026
NCT ID
NCT06708416About ONO-1110 + Placebo
ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Postherpetic Neuralgia. The current trial status is active. This product is registered under clinical trial identifier NCT06708416. Target conditions include Postherpetic Neuralgia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06752603 | Phase 2 | Recruiting |
| NCT06752590 | Phase 2 | Recruiting |
| NCT06708416 | Phase 2 | Active |
| NCT06805565 | Phase 2 | Active |
| NCT06792136 | Phase 2 | Active |
Competing Products
20 competing products in Postherpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| QUTENZA | Astellas Pharma | Approved | 85 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| MK-8291 + Placebo | Merck | Phase 1 | 33 |
| Etoricoxib + Placebo | Merck | Approved | 85 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 52 |
| MK0759 | Merck | Phase 2 | 52 |
| MK0686 | Merck | Phase 2 | 52 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 33 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 84 |
| RN624 + RN624 + Placebo | Pfizer | Phase 2 | 51 |
| T-62 | Pfizer | Phase 2 | 51 |
| pregabalin + pregabalin/PF-00489791 + Placebo | Pfizer | Phase 2 | 51 |
| PH-797804 + Placebo | Pfizer | Phase 2 | 51 |
| Placebo + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Phase 3 | 76 |
| pregabalin | Pfizer | Approved | 84 |
| T-62 Dose 1 + T-62 Dose 2 | Pfizer | Phase 2 | 51 |
| HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Levetiracetam | UCB | Phase 2 | 49 |